Abstract #3298

Longitudinal changes in diffusion basis spectrum imaging metrics of normal-appearing white matter and lesions in ocrelizumab-treated relapsing multiple sclerosis

Anika Wurl^1,2, Irene M Vavasour³, Adam Dvorak^4,5, Nathalie Ackermans¹, Cornelia Laule^3,4,5,6, David KB Li³, Robert Carruthers¹, Alex L Mackay^3,4, Roger Tam^3,7, Anne H Cross⁸, Peng Sun⁸, Sheng-Kwei Song⁸, Hideki Garren⁹, Anthony Traboulsee¹, and Shannon H Kolind^1,4,5

¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Physics, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany, ³Radiology, University of British Columbia, Vancouver, BC, Canada, ⁴Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada, ⁵International Cooperation on Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, Canada, ⁶Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada, ⁸School of Medicine, Washington University, St. Louis, MO, United States, ⁹Genentech, Inc., South San Francisco, CA, United States

Diffusion Basis Spectrum Imaging (DBSI) probes axonal and myelin damage by modeling the diffusion-weighted MRI signal as discrete anisotropic diffusion tensors while simultaneously differentiating and quantifying inflammation and edema through a modeled isotropic diffusion tensor spectrum. We studied 15 RMS patients beginning ocrelizumab treatment over two years as well as 10 healthy controls.

DBSI detected microstructural differences between RMS normal-appearing white matter, chronic and enhancing lesions, and healthy control white matter. Further, the metrics were sensitive to changes within two years of follow-up and showed improvement towards healthy control values in patients treated with ocrelizumab.

This abstract and the presentation materials are available to members only; a login is required.

Join Here